Arvinas, Inc. announced that the U.S. Food and Drug Administration approved its oral PROTAC degrader, VEPPANU (vepdegestrant), for adults with estrogen‑receptor‑positive, HER2‑negative, ESR1‑mutated advanced or metastatic breast cancer. The approval marks the first time the FDA has sanctioned a PROTAC‑based therapy, establishing a new therapeutic class and validating Arvinas’ protein‑degradation platform.
The approval was based on the VERITAC‑2 Phase 3 trial, which demonstrated a 43 % reduction in the risk of disease progression or death and a median progression‑free survival of 5 months versus 2.1 months for the comparator fulvestrant. The data were presented ahead of the anticipated June 5 PDUFA date, underscoring the strength of the clinical evidence.
The indication targets a specific subset of breast‑cancer patients, with an estimated U.S. market of 16,000–25,000 patients. The FDA’s concurrent approval of Guardant360 CDx as a companion diagnostic will enable precise identification of ESR1‑mutated patients, expanding the drug’s reach within this niche population.
Arvinas and its partner Pfizer plan to engage a third‑party commercial partner for the launch, as the company lacks an internal oncology sales infrastructure. This strategy reflects Arvinas’ focus on leveraging external expertise to bring the product to market efficiently.
Financially, Arvinas reported a decline in revenue in its most recent quarter, driven by changes in collaboration agreements and reduced revenue from the Vepdegestrant Collaboration Agreement with Pfizer. Despite the headwinds, the company’s cash position remains sufficient to fund operations into the second half of 2028, positioning it to capitalize on the new revenue stream from VEPPANU.
Management emphasized the significance of the milestone. President and CEO Randy Teel said, “Today’s FDA approval is a transformative moment for Arvinas as we achieve our first approved medicine and the first‑ever approved PROTAC therapy based on the technology we've pioneered since 2013.” Former CEO John Houston added, “With the efficacy and favorable tolerability seen in VERITAC‑2, we believe vepdegestrant, if approved, has potential to be a best‑in‑class treatment option for patients in the second‑line ESR1‑mutated setting.”
The approval was well received by investors, with analysts noting the milestone’s potential to open a new revenue stream and validate the company’s platform. The market reaction reflected confidence in the company’s ability to commercialize a first‑in‑class product despite its current lack of oncology sales infrastructure.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.